Quick Links
Past Events

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Supporters

This activity is supported by educational grants from Celgene Corporation and Lilly USA, LLC.
Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
Physicians’ Education Resource ®, LLC.
All rights reserved.

7th Annual New York Lung Cancer Symposium®

7th Annual New York Lung Cancer Symposium®

Expanding the Boundaries of Personalized Medicine
Emerging Therapeutic Targets for Squamous NSCLC Ramaswamy Govindan, MD
How to Get the Most Information From a Tumor Biopsy William Travis, MD
Panel Discussion with Cases Roman Perez-Soler, MD, 
William Travis, MD
Optimal Application of EGFR/ALK TKIs: What is the Next Step?
Overview Lecture: Who Should Receive TKIs and When? Roman Perez-Soler, MD
Resistance to EGFR TKIs: Mechanisms and Management Mark Kris, MD
State of the Art for ALK inhibition Robert C. Doebele, MD, PhD
Panel Discussion with Cases Roman Perez-Soler, MD, 
Mark Kris, MD, 
Robert C. Doebele, MD, PhD, 
Steven Vogl, MD
Advanced NSCLC: Poor-PS and Other Patients
Current Approaches for Special Populations Rogerio Lilenbaum, MD, FACP
Featured Case Discussions Roman Perez-Soler, MD,
Harry Raftopoulos, MD,
Haiying Cheng, MD
Optimizing Frontline and Maintenance Therapy in Advanced NSCLC
Choosing Optimal Frontline Therapy for Advanced, Nonsquamous NSCLC Jyoti Patel, MD
Maintenance Therapy: Which Patients, Which Approach? Mark Sockinski, MD
Panel Discussion Jyoti Patel, MD, 
Mark Sockinski, MD,
Steven Vogl, MD
Optimizing Therapy for Locoregional Disease
Radiation Oncology for Combined Modality Therapy: State of the Art Maria Werner-Wasik, MD
New Therapies and Targets on the Horizon
Emerging Roles for Hsp90 Inhibition Mark Socinski, MD
Anti-PD1 antibodies: The Arrival of Immunotherapy to Lung Cancer Scott Gettinger, MD
New Molecular Targeted Therpaies (including KRAS, ROS and RET) Naiyer Rizvi, MD

Become a Member

Forgot Password?
Filter By